iSpecimen (NASDAQ:ISPC – Get Free Report) and 10x Genomics (NASDAQ:TXG – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.
Analyst Ratings
This is a summary of current recommendations for iSpecimen and 10x Genomics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| iSpecimen | 1 | 0 | 0 | 0 | 1.00 |
| 10x Genomics | 1 | 12 | 5 | 0 | 2.22 |
10x Genomics has a consensus target price of $68.00, suggesting a potential upside of 3.29%. Given 10x Genomics’ stronger consensus rating and higher probable upside, analysts clearly believe 10x Genomics is more favorable than iSpecimen.
Earnings and Valuation
This table compares iSpecimen and 10x Genomics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| iSpecimen | $1.93 million | 1.11 | -$10.49 million | ($56.44) | -0.02 |
| 10x Genomics | $642.82 million | 13.34 | -$43.54 million | ($0.59) | -111.58 |
iSpecimen has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares iSpecimen and 10x Genomics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| iSpecimen | -2,445.40% | -524.39% | -140.42% |
| 10x Genomics | -12.18% | -9.33% | -7.30% |
Insider & Institutional Ownership
13.6% of iSpecimen shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 12.2% of iSpecimen shares are held by company insiders. Comparatively, 8.8% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility & Risk
iSpecimen has a beta of 1.54, indicating that its share price is 54% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500.
Summary
10x Genomics beats iSpecimen on 11 of the 14 factors compared between the two stocks.
About iSpecimen
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.
About 10x Genomics
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.
